Pay in 4 interest-free payments of $5.75 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
The market is driven by the expanding clinical indication of these therapies, which are now evolving from handling Type 2 diabetes to long-term chronic weight management and even cardiovascular risk reduction
Ongoing vomiting increases the risk of dehydration and needs attention
OW semaglutide significantly reduced mean HbA1c and body weight compared to OD empagliflozin, suggesting superior efficacy when added to metformin monotherapy
A GLP-1 and GIP analogue should only be offered to adults with T2DM, in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team
US$ 25.85
US$ 27.37
US$ 21.56
